What is EG 427?
EG 427 is at the forefront of gene therapy innovation, developing a unique 'pinpoint gene therapy' method. The company leverages the inherent properties of the Herpes Simplex Virus 1 (HSV-1) to achieve lifelong latency in peripheral neurons. This allows for highly specific and durable expression of transgenes, targeting severe, chronic, and localized diseases, with an initial focus on peripheral nervous system disorders. Headquartered in Paris, France, EG 427's scientific approach aims to create a substantial advancement in the gene therapy landscape.
How much funding has EG 427 raised?
EG 427 has raised a total of $48.2M across 2 funding rounds:
Series A
$20M
Series B
$28.2M
Series A (2023): $20M with participation from David Lamond & Associates
Series B (2025): $28.2M led by SCI Ventures, Bpifrance, and Andera Partners
Key Investors in EG 427
David Lamond & Associates
David Lamond & Associates is likely a financial advisory or investment firm, potentially specializing in strategic capital allocation for emerging companies, given its participation in EG 427's Series A funding.
SCI Ventures
SCI Ventures is a pioneering investment fund focused on catalyzing innovative therapies for spinal cord injury and related conditions, investing in early-stage companies developing cure-oriented treatments.
Bpifrance
Bpifrance is a French public investment bank that finances companies at every stage of their development, supporting innovation and international expansion.
What's next for EG 427?
With the recent influx of major strategic investment, EG 427 is poised for significant expansion. The company's focus on exploiting HSV-1's natural capabilities for targeted gene delivery positions it to address unmet needs in treating peripheral nervous system disorders. This capital infusion will likely fuel further research and development, clinical trials, and potential expansion into new therapeutic areas. The enterprise-level backing suggests confidence from investors in EG 427's long-term vision and its potential to disrupt the gene therapy market.
See full EG 427 company page
